Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.0 Million Offering
Press Release – New York, NY – October 1, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in its best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated warrant, priced at-the-market under Nasdaq rules. Total gross proceeds from the offering were approximately $5 million.
The SRFC team was led by partners Gregory Sichenzia and Avital Perlman and associate Christian Lichtenberger.